Flanvotumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:14, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Flanvotumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6470H9986N1714O2018S46
Molar mass145545.80 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[3]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
  2. ^ http://adisinsight.springer.com/drugs/800019264
  3. ^ http://adisinsight.springer.com/drugs/800019264


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Flanvotumab&oldid=963846711"